Meanwhile, the ATLANTIC trial reported contradictory findings that durvalumab exhibited clinical activity regardless of the status of EGFR/ALK alterations in heavily treated NSCLC with higher expression of PD-L1 [70]. Here, CD274 is linked to non-small cell lung carcinoma.